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ABSTRACT 
 
 
 
   Toxin-antitoxin systems are prevalent in different bacterial organisms and are encoded in 
the chromosomal or plasmid DNA.  The primary function of a plasmid toxin-antitoxin 
module is to stabilize the plasmid by eliminating plasmid-free daughter cells through a post 
segregation killing mechanism.  In Campylobacter jejuni, a pathogen that causes human 
gastroenteritis, multiple plasmids have been identified, but there have not been any reports on 
toxin-antitoxin systems.  In this study, a toxin-antitoxin system is identified and characterized 
in the pVir plasmid of C. jejuni IA 3902.  pVir encodes a type IV secretion system and is 
found to be involved in natural transformation and virulence in Campylobacter.  
Comparative genomic analysis of the pVir45 and pVir46 genes in C. jejuni indicates that 
they encode a putative toxin-antitoxin system that belongs to the RelE/StbE family.  Cloning 
and expression of the pVir46 gene alone in Escherichia coli inhibited bacterial growth, but 
co-expression of pVir45-46 led to the restoration of growth, confirming the functions 
deduced from comparative genomic analysis.  The plasmid stability assay in C. jejuni 
showed that the toxin-antitoxin system is necessary for maintaining the stability of pVir 
because deletion of the pVir46 gene resulted in loss of the plasmid during passage in 
conventional media.  qRT-PCR data demonstrated that expression of the pVir45-46 genes 
varied with growth phase, as early logarithmic phase had the highest level of gene 
expression.  Together these results establish that pVir45-46 encode a functional toxin-
antitoxin system in C. jejuni, which is required for ensuring the stability of the pVir plasmid.  
The stable maintenance of pVir may be necessary for optimal virulence of C. jejuni IA 3902.
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CHAPTER 1.  GENERAL INTRODUCTION 
 
Introduction 
 
   C. jejuni is a gram-negative, microaerophilic organism that causes human gastroenteritis. It 
is also increasingly associated with ovine abortions in the United States (75).  C. jejuni is 
recognized as the leading cause of foodborne illnesses in the United States with 
approximately 2.4 million reported cases annually (19).  C. jejuni  infections are described as 
a self-limiting disease often resulting in abdominal cramping, diarrhea, and fever in patients 
(66).  Severe diseases associated with C. jejuni often occur in infants, elderly, and HIV 
patients.  A well-known complication of C. jejuni infection is Guillain-Barré syndrome, a 
neurological disorder resulting in the damage of the peripheral nervous system (1).  As a 
foodborne pathogen, the incidence of Campylobacter infections is commonly linked to the 
consumption of contaminated water, unpasteurized milk, and poultry meat (22, 88). 
 
  C. jejuni contains no known identified putative toxin-antitoxin systems (86).  The toxin-
antitoxin system is considered to be an addictive genetic element in which the transcription 
of the two neighboring genes are auto regulated and the two loci are overlapping with each 
other (50).  In this study, a toxin-antitoxin system is identified and characterized in the pVir 
plasmid of C. jejuni IA 3902 strain.  Comparative genomic analysis of the pVir45 and pVir46 
genes in C. jejuni indicates that the toxin-antitoxin system belong to the RelE/StbE family.  
Cloning and expression of the pVir46 gene alone in Escherichia coli inhibited bacterial 
growth, but when pVir45-46 is co-expressed, bacterial growth was restored.  The plasmid 
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stability assay in C. jejuni showed that the entire toxin-antitoxin system is necessary for 
plasmid maintenance, but deletion of the pVir46 gene resulted in plasmid loss.  The 
identified toxin-antitoxin system in pVir of C. jejuni IA 3902 may contribute to 
Campylobacter virulence by maintaining plasmid stability.  This study represents the first 
report on a functional toxin-antitoxin system in Campylobacter. 
 
Thesis Organization 
 
   The thesis is organized into three chapters.  The first chapter of this thesis is a literature 
review about the characteristics of C. jejuni and the toxin-antitoxin stability system.  The 
second chapter describes the identification and characterization of a toxin-antitoxin system in 
the pVir plasmid of C. jejuni IA 3902.  The thesis concludes with a general conclusion of the 
experimental results. 
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Literature review 
 
C. jejuni microbiology and genomics 
 
   C. jejuni is a gram-negative organism that has spiral or helical shaped morphology.  C. 
jejuni is a motile bacterial organism consisting of either uni or bipolar flagella attached to its 
polar ends providing it with a corkscrew motion essential to its virulence.  C. jejuni is grown 
in a microaerophilic environment for optimal growth at 5% O2, 10% CO2, and 85% N2 at a 
temperature of 37 
o
C or 42 
o
C (87). 
 
   The pathogenic mechanisms of C. jejuni are still poorly defined, but more knowledge about 
the virulent determinants is being discovered with the advance of sequencing and annotation 
of C. jejuni genomes.  Currently, there are 16 sequenced genomes of C. jejuni including RM 
1221, 81-176, 81116, IA 3902, ICDCCJ07001, M1, NCTC 11168, S3, CG8486, CG8421, 
BH-01-0142, HB93-13, 260.94, CF93-6, 84-25 and doylei.  C. jejuni genomes consist of a 
circular chromosome ranging from approximately 1.6 to 1.8 megabases in size.   The 
sequence of C. jejuni NCTC 11168 reveals that 94.3% of the entire genome are coding 
sequences (61).  The genome of C. jejuni has a relatively low G+C content (~30%), which is 
especially low in the lipooligosaccharide (LOS) and extracellular polysaccharide (EP) 
regions (61).  Some unique features of the C. jejuni NCTC 11168 genome include the lack of 
insertion sequences and repeat sequences.  The organization of genes in C. jejuni appears to 
be functionally unrelated and scattered randomly throughout the entire genome.  The genome 
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of C. jejuni contains a high rate of hypervariable sequences particularly in the genes of 
biosynthesis or modification of surface structures (54). 
 
   C. jejuni 07001 was isolated from a stool sample obtained from an individual who suffered 
from Guillain-Barré syndrome (GBS) from an outbreak that occurred in China in 2007 (92).  
C. jejuni 07001 consists of a chromosome and a tetracycline resistant plasmid.  The pTet 
plasmid is 41,742 base pairs in length and is similar to the 81-176 pTet plasmid.  Genomic 
analysis of C. jejuni 07001 revealed high sequence variability in the regions encoding for 
LOS, flagella modification, and polysaccharide capsular biosynthesis.  In C. jejuni 07001, 
there are 32 identified genes unique to this strain including McrB, which is part of the 
McrBC restriction endonuclease system, and FspA2, which is a flagellum-secreted protein 
inducing epithelial cell apoptosis (91).  The genes of cgtA, cgtB, and cst-II in C. jejuni 07001  
are involved with LOS ganglioside mimicry which are commonly present in strains 
associated with Guillain-Barré syndrome (55). 
 
   C. jejuni M1 was a strain isolated from a human patient who developed enteritis after 
visiting a poultry abattoir (26).  C. jejuni M1 strain has similar genomic traits with C. jejuni 
81116.  However, the M1 strain has unique phenotypic characteristics compared to other C. 
jejuni strains as it has poor motility, is a poor colonization in chickens, and has straight 
morphology.  C. jejuni M1 is identified to have cadF which is important for chicken 
colonization (46) and porA, which is a major outer membrane protein needed for adhesion 
(53).  Interestingly, the capA gene is absent in the M1 strain which is associated with 
adherence in human cell lines and important in chicken colonization (4).  The gene 
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CJM1_0038 encodes gamma-glutamyltranspeptidase, which is essential for C. jejuni 
colonization in the avian intestine and is conserved in C. jejuni 81116 and 81-176 (26). 
 
   C. jejuni subspecies doylei is different from the other C. jejuni strains in several aspects.  It 
is primarily obtained from clinical samples associated with bacteremia (44).  The doylei 
strain has some unique phenotypic characteristics that distinguish it from other C. jejuni 
strains as it does not readily grow at 42 
o
C because culturing methods for C. jejuni select 
against C. jejuni doylei and it is susceptible to cephalothin.  C. jejuni doylei lacks L-arginine 
arylamidase and ɣ-glutamyl transferase activity.  Comparative genomic analysis conducted 
by microarray technology indicates that C. jejuni doylei does not contain genes for nitrate 
reductase and cytolethal distending toxin (59). 
 
   C. jejuni 81-176 contains two plasmids approximately 35 kb in size.  One plasmid known 
as the pTet plasmid contains the tetO gene, making it resistant to tetracycline.  Another 
plasmid in 81-176 is known as the pVir plasmid, which contains significant homology to a 
cag pathogenicity island found in Helicobacter pylori (5).  The pVir plasmid plays an 
important role in the invasion of C. jejuni.  C. jejuni 81-176 contains an additional DMSO 
reductase system, which may be important for respiration in oxygen limited conditions of the 
intestinal tract.  C. jejuni 81-176 encodes for homologs of C4-dicarboxylate carriers, which 
are active in metabolism under anaerobic conditions.  Interestingly, 81-176 contains a gene 
for glycerol-3-phosphate transporter, allowing for the removal of glycerol-3-phosphate 
providing this strain with a metabolic advantage (39). 
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   C. jejuni strain 81116 is a human isolate obtained in a 1982 waterborne outbreak (63).  The 
strain 81116 contains 17 homopolymeric G tract regions, which are significantly fewer than 
other previously sequenced C. jejuni strains.  C. jejuni strain 81116 has a 6.5-kb region that is 
duplicated in its genome, which is a distinguishing feature of this strain.  This strain lacks 
some of the genes necessary for iron uptake as it doesn’t have the CfrA and Cj0178 genes.  
This strain contains a single gene that encodes for TonB, while other C. jejuni strains have 
multiple copies of TonB (35). 
 
   C. jejuni strain S3 originated from the feces of a chicken and is the second poultry isolate 
to be sequenced and annotated.  Some unique features of this strain are that it is nonmotile 
and considered to be a weak colonizer of poultry (16).  The S3 strain consists of a circular 
chromosome and the pTET plasmid.   
 
   The genome size of C. jejuni strain RM1221 is larger than that of NCTC 11168.  The 
distinguishing feature of this strain is that it contains four C. jejuni-integrated elements 
(CJIE) (60).  CJIE1 is located upstream of argC and encodes proteins that are similar in 
function to bacteriophage Mu.  CJIE3 is most likely an integrated plasmid since it is located 
at the 3 prime end of the arginyl-tRNA.  CJIE2 and CJIE4 encode for methylases, 
endonucleases, and repressors for phage related activities. 
 
   C. jejuni IA 3902 was isolated from the placenta of an aborted sheep.  This strain is 
responsible for the majority of the ovine abortions occurring in the United States (75).  C. 
jejuni IA 3902 is similar in genomic composition to NCTC 11168.  The genome of IA 3902 
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consists of a chromosome with an inserted tetO gene, making it tetracycline resistant, and the 
pVir plasmid carrying a putative toxin-antitoxin stability system.  A unique feature of this 
genome is that the tetO gene is inserted in the chromosome instead of being carried on a 
plasmid like in other C. jejuni strains. 
 
   Strain CG8486 was isolated in Thailand from an individual who experienced dysentery.  
CG8486 has a chromosome that is syntenic with the NCTC 11168 chromosome except for 
some random insertions and deletions scattered on the genome (68).  The tetO gene is carried 
in the plasmid of CG8486, making it tetracycline resistant.  The C. jejuni isolate has remnant 
of a degenerated virulence gene that shows significant sequence homology to the filamentous 
hemagglutinin in C. lari RM2100 (68).  Additionally, CG8486 contains a cluster of genes 
that encode for arsenate resistance, such as the arsB and arsC genes. 
 
   The C. jejuni isolates of CG8421 and BH-01-0142 do not synthesize glycolipid mimics 
(69).  Both of these strains were isolated from individuals after diarrheal episodes.  
Surprisingly, these strains have significantly lower levels of invasion in INT407 cell line 
compared with 81-176 (69).  CG8421 contains the tetO gene in the chromosomal DNA, 
making it tetracycline resistant.  CG8421 has the ability to survive in phosphate limited 
conditions as it contains phosphate utilization pathway. 
 
   C. jejuni 84-25 was initially isolated from the cerebrospinal fluid of a patient diagnosed 
with meningitis (8).  C. jejuni 84-25 has a greater resistance to reactive nitrogen species than 
81-176, suggesting its increased virulence and explaining why it caused a systemic clinical 
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manifestation (41).  The sequence of this genome will likely facilitate the identification of the 
genes needed for antimicrobial defenses or resistance to nitrosative stress. 
 
   Recently, a greater emphasis has been placed on the virulent determinants of C. jejuni that 
cause Guillain-Barré syndrome.  The following additional C. jejuni genomes have been 
sequenced:  HB93-13, 260.94, and CF93-6.  HB93-13 was isolated from an individual from 
China, and this isolate was shown to express GM1 and GD1a ganglioside structure types 
(38).  HB93-13 has the htrB gene, which is needed for its survival under environmental 
stresses ensuring its survival (67).  The CF93-6 strain was isolated from a patient with MFS 
in Japan and produces GT1a gangliosides that are cross reactive with anti-GQ1b antibodies 
(45).  C. jejuni 260.94 was isolated from a patient in South Africa, which was associated with 
the most common type of GBS (89).  These C. jejuni strains have similar genomic structures 
and sequence homology in the LOS region, further suggesting the association of unique LOS 
structures with GBS. 
 
C. jejuni infections 
 
   C. jejuni infections are a significant cause of human gastroenteritis in the United States and 
other countries resulting in the symptoms of fever and diarrhea in patients.  The C. jejuni 
infections are a common cause of bacterial diarrhea in both developing and industrial 
countries, but the nature of infection is different (2).  In developing nations, children and 
adults infected by C. jejuni appear to have asymptomatic infections and outbreaks of the 
infection are rare compared to industrialized nations.  In tropical climates, the infection is 
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hyperendemic among children under the age of two years (14).  C. jejuni has been identified 
as the leading cause of foodborne illness primarily acquired from the consumption and 
handling of chickens in industrialized countries (21).  C. jejuni infections are often self-
limiting as antibiotic treatment is typically not needed for treatment.  Clinical manifestations 
that can arise from Campylobacter are diarrhea from watery to bloody, abdominal cramps, 
fever, and bacteremia.  Individuals with the infection have red blood cells and fecal 
leukocytes in their stool samples (7).  Experimental studies have shown that increased cases 
of campylobacteriosis occur in individuals who are immunosuppressed like HIV patients, 
infants, and elderly (78, 79). 
 
   C. jejuni infections are often associated as a trigger in the development of Guillain-Barré 
syndrome (GBS).  GBS is a debilitating disorder that impairs the peripheral nervous system 
resulting in severe neurological damage.  The risk of actually contracting GBS from prior C. 
jejuni infections depends primarily on the particular Campylobacter serotypes as O:19 and 
O:41 are more frequently linked with GBS than others (3).  The actual probability of 
contracting GBS after Campylobacter infection is relatively low as it only occurs in 1 out of 
1000 reported cases infected by Campylobacter (1).  After C. jejuni infection, GBS 
symptoms occur approximately one to three weeks after diarrheal symptoms (2).  The 
pathogenesis of C. jejuni triggered GBS appears to be related to autoimmunity triggered by 
molecular mimicry between the LOS of C. jejuni and the peripheral nerve glycolipids (90). 
 
   Miller-Fisher Syndrome (MFS) is a less common variant of GBS and is known to cause 
ataxia and ophthalmoplegia (72).  MFS is also associated with molecular mimicry between 
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C. jejuni infection and the neural gangliosides (32).  Patients who are diagnosed with MFS 
have serum antibodies for GQ1b and GT1a present on motor nerve terminals (12). 
 
   A chronic disorder called Reiter’s syndrome is also associated with C. jejuni infections.  
Reiter’s syndrome causes inflammatory arthritis primarily in large joints like the knee or 
back of humans.  Patients who have contracted Reiter’s syndrome are positive for the Human 
Leukocyte Antigen B27 which is an inherited marker for the prevalence of rheumatoid 
diseases.  Population studies have suggested that the prevalence of C. jejuni infection could 
have triggered reactive arthritis as approximately 7% of the patients with Reiter’s syndrome 
in Finland hospital were positive for C. jejuni in their stool samples (36). 
 
Epidemiologic features of C. jejuni infection 
 
   C. jejuni is a commensal organism which colonizes the normal gastrointestinal tracts of 
food producing animals.  C. jejuni has a widespread animal reservoir including chickens, 
turkeys, sheep, cattle, swine, and wild birds such as geese (49) and seagulls (31).  
Transmission of C. jejuni to a human host occurs primarily through the consumption of 
contaminated foods of animal origins.  Sporadic cases of C. jejuni infection in humans are a 
result of the ingestion of undercooked poultry, unpasteurized milk, and contaminated 
drinking water (9).  C. jejuni infection can also be acquired through contact with pets or 
infected individuals, and travel to developing nations (6). 
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   Experimental and epidemiological studies on the transmission of C. jejuni in broiler 
chickens support the theory that C. jejuni is horizontally transmitted on farms (74).  Different 
from Salmonella, there is no solid evidence for vertical (or egg-borne) transmission of C. 
jejuni from breeder flocks to broiler flocks (77).  The prevalence of C. jejuni in broiler 
chickens is primarily influenced by the environmental conditions on the poultry farms, 
indicating that horizontal transmission is the primary mode of spread.  The source of 
contamination in poultry is attributable to multiple factors, such as contaminated drinking 
water, presence of domesticated animals, rodents, and poor hygiene of farm workers (9). 
 
Treatment of C. jejuni infections 
 
   C. jejuni infections are often self-limiting and do not need antibiotics for treatment, but 
under certain circumstances, medication is needed to alleviate severe symptoms.  Antibiotic 
therapy is often prescribed to patients who are immunocompromised or exhibit severe 
clinical symptoms from the infection (6).  C. jejuni is known to be intrinsically resistant to 
several antibiotics, such as vancomyin, rifampin, trimethoprim, amoxicillin, ampicillin, 
metronidazole, and cephalosporin (2).  Fluoroquinolone and erythromycin have been the 
antibiotics that are commonly prescribed for the treatment of C. jejuni infections.  
Fluoroquinolones are frequently used for the treatment of enteric infections, because it can 
alleviate the infection by different pathogens, such as Salmonella and Campylobacter.  
Recently, many Campylobacter strains have become fluoroquinolone resistant due to its 
widespread use in food animal production and human medicine, and due to the fact that C. 
jejuni is highly mutable to fluoroquinolone treatment (23, 40).  In general, macrolide (e.g. 
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erythromycin) is now the most effective drug to treat Campylobacter infections and  it is 
acid-resistant and incompletely absorbed in the gut (2).  Erythromycin is easy and safe to be 
administered to immunosuppressed or immune-immature patients, such as children and 
pregnant women, and has low rates of resistance in Campylobacter species. 
 
Prevention of C. jejuni transmission 
 
   To control C. jejuni transmission through the food chain, it is imperative to use a farm-to-
folk approach that includes reducing its prevalence on farms, minimizing contamination of 
carcasses in processing plants, and ultimately educating consumers for proper handling and 
cooking poultry products.  C. jejuni infections are known to occur from the consumption of 
undercooked poultry, unpasteurized milk, and untreated water (22, 56, 81).  Overall, 
enhanced efforts are being made to develop intervention measures at both pre- and post-
harvest stages. 
 
   The prevention of C. jejuni infections begins with limiting the bacterial load on poultry 
farms, but currently there are no effective and practical strategies that can be implemented to 
reduce Campylobacter colonization in live birds.  Additionally, a number of studies have 
been performed to reduce carcass contamination in slaughter houses (83, 84).  The 
implementation of disinfecting strategies during the processing steps can reduce the levels of 
C. jejuni on the carcasses.  The use of chlorinated sprays have been used to clean the surfaces 
in slaughter facilities, which was reported to have up to a 100-fold reduction in C. jejuni 
contamination of the carcasses (52).  A freeze-thaw chilling method is used to reduce the 
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contamination of pig and poultry processing by up to 100-fold reduction (57).  Experimental 
studies have shown that poultry meat subjected to gamma radiation was successful in 
reducing C. jejuni (13, 62).  However, the use of irradiation technology as a food safety 
measure is still not accepted by many consumers.  Regardless, the precautions taken by the 
food industry during the slaughter and processing steps help to minimize the risk of C. jejuni 
transmission to consumers. 
 
   Currently, there are no vaccines available for the prevention of C. jejuni infection in 
animals or humans, but experimental studies have shown promises for vaccines against the 
disease.  An oral vaccine of inactivated C. jejuni whole cell administered in broiler chickens 
resulted in reductions in the colonization of C. jejuni up to 93% compared with unvaccinated 
chickens (71).  The whole cell vaccines increased the levels of anti C. jejuni secretory IgA 
antibodies in the vaccinated chickens compared to the non-vaccinated controls.  An 
inactivated whole cell vaccine of 81-176 showed protection levels between 80 to 100% 
against C. jejuni infection in ferrets (11).  An experimental study evaluated the effectiveness 
of a truncated recombinant flagellin subunit vaccine in mice which was administered by a 
nasal route and showed a high level of protection against C. jejuni (47).  There are still no 
commercial vaccines developed against C. jejuni, but these experimental vaccines evaluated 
in model organisms provide hope for the development of effective vaccines. 
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Toxin-Antitoxin systems and plasmid maintenance 
 
   Toxin-antitoxin (TA) systems are commonly found on plasmid DNA and functions to 
maintain plasmid stability (42). TA genes are also present in chromosomal DNA, where their 
functions can vary significantly (50).  TA systems are discovered as single or multiple copies 
in bacterial organisms, but no TA systems have been identified in C. jejuni (86).  The 
organizations of a TA system in bacterial organisms are found in two possible arrangements.  
The most common organization of a TA system is where the antitoxin gene precedes the 
stable toxin gene.  An alternative arrangement of the TA system is where the toxin gene 
precedes the antitoxin gene and has a second promoter before the antitoxin gene.  A 
distinguishing feature of the TA stability systems is that the transcription of the genes are 
autoregulated by the protein products (50).  The toxin and antitoxin genes have a region 
where the stop codon of the antitoxin gene and start codon of the toxin gene are overlapping 
with each other indicating translational coupling (93). 
 
   The regulation of plasmid stability by a TA module occurs when the antitoxin binds to the 
toxin to neutralize its toxic effects at the steady state.  The antitoxin is synthesized at greater 
rates to inhibit the function of the toxin, but if there is a disruption to this continuous 
synthesis it would allow the toxin to be free and potentially kill the host (29).  When the 
toxin is liberated, daughter cells that do not inherit the copy of the plasmid with an intact TA 
system will eventually be eliminated by a post-segregational killing mechanism by the 
deleterious activity of the toxin (86).  Plasmid-encoded TA systems appear to increase the 
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fitness and prevalence of plasmids in the bacterial population through a post-segregational 
killing mechanism (86). 
 
Diversity of plasmid addiction systems 
 
    There are three different types of TA systems prevalent in bacterial organisms.  Type I TA 
systems consist of an antisense RNA antitoxin and a proteic toxin complex and was first 
represented by the Hok-Sok system in the R1 plasmid (30).  The toxins of type I are 
primarily hydrophobic in nature and are small in size resulting in the damage of the cell 
membrane (86).  The translation of the toxin is inhibited when the protein toxin is bound to 
the RNA antitoxin (37).  The difference of having an antitoxin RNA from an antitoxin 
protein is that its interaction with the toxin results in an irreversible step as mRNA cleavage 
occurs.  The antisense RNA is usually encoded on the antisense strand compared to its target 
toxin and has significant overlap with the toxin mRNA.  Type I TA systems are not as 
prevalent as type II since the identification of the type I toxins are difficult due to its smaller 
size and having a shorter transmembrane helix (25). 
 
   Type II TA systems are composed of proteins for both the toxin and antitoxin components.  
Genetically, the antitoxin gene is located upstream of the toxin gene forming an operon.  
Type II TA systems are different in its regulation from the type I TA systems is regulated at 
the protein level.  The type II TA systems are also widely distributed on bacterial 
chromosomal DNA with multiple copies, but the function of the chromosomally encoded 
complexes is not clearly defined.  Type II TA systems have been determined to function in 
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post-segregation killing of plasmid-free cells (86).  In type II TA systems, the antitoxin 
protein is more likely to be degraded by the host organism’s protease than the toxin, resulting 
in growth impairment or cell death in the bacterial host lacking a functional TA system.   
 
   The third type of TA system consists of a direct interaction between an RNA antitoxin and 
toxin protein.  The ToxIN system discovered in the phytopathogen Erwinia carotovora 
functions in the abortion of infections by different phages (24).  The toxI gene suppresses the 
bacteriostatic effects of the ToxN protein as it prevents phage replication or synthesis.   
 
Cellular targets of RelBE TA system 
 
   The RelBE family of TA system consists of antagonist RelB antitoxin and RelE toxin, 
which bind together to form the non-toxic RelBE TA system (27).  The overexpression of the 
relE toxin gene results in bacteriostatic effects as it significantly reduces the cell growth and 
inhibits translation (33, 64).  The relBE loci has been determined to function in maintaining 
plasmid stability (34).  The RelE toxin inhibits translation by cleaving mRNA at the 
ribosomal A-site between the second and third bases of the A-codon site in vitro.  Release 
factor I is known to control the amount of mRNA cleavage occurring as it binds to the 
ribosomal A-site (65) limiting the cleavage from the RelE protein.  Under in vivo conditions, 
RelE cleavage occurs on the coding strands regardless if ribosomes are present. 
 
   Crystal structure analysis of an archaeal RelBE TA system in Pyrococcus horikoshii was 
compared to other families of TA systems.  The experimental evidence shows that RelB 
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lacks a hydrophobic core and wraps around the surface of RelE (80).  RelE has hydrophobic 
properties as it folds into an α/β structure while the RelB lacks any tertiary structure, making 
it susceptible to degradation from the cellular Lon proteases (85).  As plasmid loss occurs, 
the Lon protease degrades the antitoxin, activating the effects of the RelE toxin.  The Lon 
cellular protease degrades free and bound forms of the RelB allowing the inhibition of 
translation by the RelE.  The interaction between RelB and RelE creates an inactive complex 
of RelBE. 
 
Type II TA families 
 
   There have been nine type II TA families identified and characterized to date.  The families 
of type II toxin-antitoxin systems in bacteria are the following:  Ccd, RelBE, HigBA, HipAB, 
ParDE, Pem and MazEF, Phd/doc, VapBC, and ω-ε-ξ (86).  The TA systems have been 
classified into two distinct groups of two component and three component gene families.  
These TA systems have been discovered on either plasmid or chromosomal DNA. 
 
   The relBE locus in the chromosome of Escherichia coli K-12 consists of a RelB antitoxin 
and RelE cytotoxin (33).  The overexpression of RelE results in the inhibition of cell growth 
in the host organism while RelB prevents the toxic effect of RelE.  RelE is degraded by Lon 
protease in order to form a tight binding with RelB to neutralize its toxic effects.  The relBE 
locus is also discovered on the plasmids of Escherichia coli, Plesiomonas shigelloides, 
Acetobacter europaeus, and Butyrivibrio fibrisolvens (28).  Experimental studies have 
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determined that plasmid and chromosomal relBE loci both function in plasmid stability by 
killing plasmid-free cells, making it an unique property of the RelBE TA family (33). 
 
   The ccd locus is located in the F plasmid of E. coli and functions in plasmid maintenance 
by killing plasmid-free daughter cells.  The Ccd TA system is primarily discovered in 
plasmids and in the chromosomes of a few gram-negative bacteria (58).  The ccd locus 
consists of the ccdA and ccdB gene pair, in which the CcdB prevents cell division while 
CcdA suppresses the activity of the CcdB toxin.  The CcdB toxin inhibit DNA replication by 
the inactivation of the DNA gyrase (18).  The binding of the ccdA and ccdB genes prevent 
the activation of the Lon-dependent proteolysis of CcdA (85). 
 
   The higBA locus was initially discovered in the Rts1 plasmid of Proteus vulgaris (82).  The 
higBA TA system is found on both plasmids and chromosomes and the first chromosomal 
higBA was found in Vibrio cholera (10).  The HigBA TA system consists of the HigA 
antitoxin and HigB toxin which inhibits cellular growth, but the specific inhibitory 
mechanisms of the toxin is still unknown.  The gene organization of the higBA loci is 
different from other TA families as the higB toxin gene is upstream of the higA antitoxin 
gene, which controls the expression of higB (10). 
 
   The parDE TA system was originally found on the RK2 plasmid in which it functions in 
plasmid maintenance by a post-segregation killing mechanism.  The parDE locus consists of 
the ParD antitoxin and ParE toxin, which form a tetrameric ParDE TA complex that 
autoregulates the transcription of the parDE locus (43).  The ParE toxin inhibits DNA 
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replication by the inactivating of the DNA gyrase.  The parDE homologues are found in both 
plasmid and chromosomal DNA. 
 
   The ω-ε-ξ TA family was initially discovered in the pSM19035 plasmid of Streptococcal 
pyogenes and is the only TA family that consists of three components (94).  The ξ gene was 
determined to be a cytotoxin by its toxic activity in Bacillus subtillis, E. coli, and 
Saccharomyces cerevisiae (94).  The ξ cytotoxin is unique compared to other toxins as it is 
made of 287 amino acids which is significantly larger than the average composition of 100 
amino acids (28).  The ε gene functions as an antitoxin which prevents the toxic effect of the 
ξ toxin through a direct protein interaction.  The ω gene regulates transcription of the entire 
locus as it encodes for an autorepressor.  The ω gene product strictly regulates the ω-ε-ξ 
locus, and it is not directly involved in the killing-anti-killing mechanism (20). 
 
   The vapBC locus was found in the virulence plasmid of Salmonella dublin (70).  The 
experimental study characterized the function of the genes of vapB and vapC and found that 
VapB is an antitoxin while VapC is a toxin.  The specific mechanism for the expression of 
the toxin gene is still unknown, but it was determined that VapB and VapC are involved in 
plasmid maintenance.  The vapBC TA family has been discovered in archaeal species such as 
Sulfolobus solfataricus and hypothesized to function in microbial stress response (15). 
 
   The phd/doc locus was discovered in the P1 plasmid, which lysogenizes E. coli.  Phd is the 
antitoxin that neutralizes the toxic effects of Doc by forming a Phd2Doc trimeric complex.  
The Phd protein is responsible in autoregulating the phd-doc operon while the Doc toxin 
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functions in translational inhibition (51).  The protease of ClpXP degrades the Phd antitoxin 
leading to the liberation of the toxin gene (48).  The primary role of the Doc toxin is to 
eliminate plasmid-free cells. 
 
   The pem loci are located in the plasmid of R100 and function in the stabilization of the 
plasmids by eliminating the growth of plasmid-free cells.  The pem loci are organized in the 
typical arrangement of other TA systems with the antitoxin gene preceding the toxin gene.  
The pem loci encode for the antitoxin genes of PemI and the toxin genes consist of PemK 
which inhibits the initiation of replication most likely in the DnaB helicase (73).  
Experimental evidence has indicated this class of toxin family is bacteriostatic in nature as it 
prevents the growth of cells and does not kill plasmid-free cells. 
 
   The hipBA loci are located in the E. coli chromosome.  HipA is a toxin and HipB is 
antitoxin which binds to HipA represses the hipBA operon (17).  The hipBA loci are 
organized in the typical arrangement of other TA systems with the antitoxin gene preceding 
the toxin gene.  HipA contains a serine/threonine kinase which phosphorylates elongation 
factor-Tu indicating the possibility of a persistence mechanism (76). 
 
 
 
 
 
21 
 
References 
 
1. Allos, B. M. 1997. Association between Campylobacter infection and Guillain-Barré 
syndrome. J Infect Dis 176 Suppl 2:S125-128. 
2. Allos, B. M. 2001. Campylobacter jejuni Infections:  Update on Emergining Issues 
and Trends, p. 1201-1206, vol. 32. Clinical Infectious Diseases. 
3. Allos, B. M., F. T. Lippy, A. Carlsen, R. G. Washburn, and M. J. Blaser. 1998. 
Campylobacter jejuni strains from patients with Guillain-Barré syndrome. Emerg 
Infect Dis 4:263-268. 
4. Ashgar, S. S., N. J. Oldfield, K. G. Wooldridge, M. A. Jones, G. J. Irving, D. P. 
Turner, and D. A. Ala'Aldeen. 2007. CapA, an autotransporter protein of 
Campylobacter jejuni, mediates association with human epithelial cells and 
colonization of the chicken gut. J Bacteriol 189:1856-1865. 
5. Bacon, D. J., R. A. Alm, D. H. Burr, L. Hu, D. J. Kopecko, C. P. Ewing, T. J. 
Trust, and P. Guerry. 2000. Involvement of a plasmid in virulence of 
Campylobacter jejuni 81-176. Infect Immun 68:4384-4390. 
6. Blaser, M. J. 1997. Epidemiologic and clinical features of Campylobacter jejuni 
infections. J Infect Dis 176 Suppl 2:S103-105. 
7. Blaser, M. J., I. D. Berkowitz, F. M. LaForce, J. Cravens, L. B. Reller, and W. L. 
Wang. 1979. Campylobacter enteritis: clinical and epidemiologic features. Ann 
Intern Med 91:179-185. 
22 
 
8. Blaser, M. J., G. P. Perez, P. F. Smith, C. Patton, F. C. Tenover, A. J. Lastovica, 
and W. I. Wang. 1986. Extraintestinal Campylobacter jejuni and Campylobacter coli 
infections: host factors and strain characteristics. J Infect Dis 153:552-559. 
9. Blaser, M. J., D. N. Taylor, and R. A. Feldman. 1983. Epidemiology of 
Campylobacter jejuni infections. Epidemiol Rev 5:157-176. 
10. Budde, P. P., B. M. Davis, J. Yuan, and M. K. Waldor. 2007. Characterization of a 
higBA toxin-antitoxin locus in Vibrio cholerae. J Bacteriol 189:491-500. 
11. Burr, D. H., D. Rollins, L. H. Lee, D. L. Pattarini, S. S. Walz, J. H. Tian, J. L. 
Pace, A. L. Bourgeois, and R. I. Walker. 2005. Prevention of disease in ferrets fed 
an inactivated whole cell Campylobacter jejuni vaccine. Vaccine 23:4315-4321. 
12. Chiba, A., S. Kusunoki, T. Shimizu, and I. Kanazawa. 1992. Serum IgG antibody 
to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 
31:677-679. 
13. Clavero, M. R., J. D. Monk, L. R. Beuchat, M. P. Doyle, and R. E. Brackett. 
1994. Inactivation of Escherichia coli O157:H7, Salmonellae, and Campylobacter 
jejuni in raw ground beef by gamma irradiation. Appl Environ Microbiol 60:2069-
2075. 
14. Coker, A. O., R. D. Isokpehi, B. N. Thomas, K. O. Amisu, and C. L. Obi. 2002. 
Human campylobacteriosis in developing countries. Emerg Infect Dis 8:237-244. 
15. Cooper, C. R., A. J. Daugherty, S. Tachdjian, P. H. Blum, and R. M. Kelly. 2009. 
Role of vapBC toxin-antitoxin loci in the thermal stress response of Sulfolobus 
solfataricus. Biochem Soc Trans 37:123-126. 
23 
 
16. Cooper, K. K., M. A. Cooper, A. Zuccolo, B. Law, and L. A. Joens. 2011. 
Complete Genome Sequence of Campylobacter jejuni Strain S3. J Bacteriol 
193:1491-1492. 
17. Correia, F. F., A. D'Onofrio, T. Rejtar, L. Li, B. L. Karger, K. Makarova, E. V. 
Koonin, and K. Lewis. 2006. Kinase activity of overexpressed HipA is required for 
growth arrest and multidrug tolerance in Escherichia coli. J Bacteriol 188:8360-8367. 
18. Critchlow, S. E., M. H. O'Dea, A. J. Howells, M. Couturier, M. Gellert, and A. 
Maxwell. 1997. The interaction of the F plasmid killer protein, CcdB, with DNA 
gyrase: induction of DNA cleavage and blocking of transcription. J Mol Biol 
273:826-839. 
19. Crushell, E., S. Harty, F. Sharif, and B. Bourke. 2004. Enteric Campylobacter: 
purging its secrets? Pediatr Res 55:3-12. 
20. de la Hoz, A. B., S. Ayora, I. Sitkiewicz, S. Fernández, R. Pankiewicz, J. C. 
Alonso, and P. Ceglowski. 2000. Plasmid copy-number control and better-than-
random segregation genes of pSM19035 share a common regulator. Proc Natl Acad 
Sci U S A 97:728-733. 
21. Deming, M. S., R. V. Tauxe, P. A. Blake, S. E. Dixon, B. S. Fowler, T. S. Jones, 
E. A. Lockamy, C. M. Patton, and R. O. Sikes. 1987. Campylobacter enteritis at a 
university: transmission from eating chicken and from cats. Am J Epidemiol 126:526-
534. 
22. Doyle, M. P., and D. J. Roman. 1982. Prevalence and survival of Campylobacter 
jejuni in unpasteurized milk. Appl Environ Microbiol 44:1154-1158. 
24 
 
23. Endtz, H. P., G. J. Ruijs, B. van Klingeren, W. H. Jansen, T. van der Reyden, 
and R. P. Mouton. 1991. Quinolone resistance in Campylobacter isolated from man 
and poultry following the introduction of fluoroquinolones in veterinary medicine. J 
Antimicrob Chemother 27:199-208. 
24. Fineran, P. C., T. R. Blower, I. J. Foulds, D. P. Humphreys, K. S. Lilley, and G. 
P. Salmond. 2009. The phage abortive infection system, ToxIN, functions as a 
protein-RNA toxin-antitoxin pair. Proc Natl Acad Sci U S A 106:894-899. 
25. Fozo, E. M., M. R. Hemm, and G. Storz. 2008. Small toxic proteins and the 
antisense RNAs that repress them. Microbiol Mol Biol Rev 72:579-589, Table of 
Contents. 
26. Friis, C., T. M. Wassenaar, M. A. Javed, L. Snipen, K. Lagesen, P. F. Hallin, D. 
G. Newell, M. Toszeghy, A. Ridley, G. Manning, and D. W. Ussery. 2010. 
Genomic characterization of Campylobacter jejuni strain M1. PLoS One 5:e12253. 
27. Galvani, C., J. Terry, and E. E. Ishiguro. 2001. Purification of the RelB and RelE 
proteins of Escherichia coli: RelE binds to RelB and to ribosomes. J Bacteriol 
183:2700-2703. 
28. Gerdes, K. 2000. Toxin-antitoxin modules may regulate synthesis of macromolecules 
during nutritional stress. J Bacteriol 182:561-572. 
29. Gerdes, K., S. K. Christensen, and A. Løbner-Olesen. 2005. Prokaryotic toxin-
antitoxin stress response loci. Nat Rev Microbiol 3:371-382. 
30. Gerdes, K., J. E. Larsen, and S. Molin. 1985. Stable inheritance of plasmid R1 
requires two different loci. J Bacteriol 161:292-298. 
25 
 
31. Glünder, G., U. Neumann, and S. Braune. 1992. Occurrence of Campylobacter 
spp. in young gulls, duration of Campylobacter infection and reinfection by contact. 
Zentralbl Veterinarmed B 39:119-122. 
32. Goodyear, C. S., G. M. O'Hanlon, J. J. Plomp, E. R. Wagner, I. Morrison, J. 
Veitch, L. Cochrane, R. W. Bullens, P. C. Molenaar, J. Conner, and H. J. 
Willison. 1999. Monoclonal antibodies raised against Guillain-Barré syndrome-
associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides 
and paralyze muscle-nerve preparations. J Clin Invest 104:697-708. 
33. Gotfredsen, M., and K. Gerdes. 1998. The Escherichia coli relBE genes belong to a 
new toxin-antitoxin gene family. Mol Microbiol 29:1065-1076. 
34. Grønlund, H., and K. Gerdes. 1999. Toxin-antitoxin systems homologous with 
relBE of Escherichia coli plasmid P307 are ubiquitous in prokaryotes. J Mol Biol 
285:1401-1415. 
35. Guerry, P., J. Perez-Casal, R. Yao, A. McVeigh, and T. J. Trust. 1997. A genetic 
locus involved in iron utilization unique to some Campylobacter strains. J Bacteriol 
179:3997-4002. 
36. Hannu, T., L. Mattila, H. Rautelin, P. Pelkonen, P. Lahdenne, A. Siitonen, and 
M. Leirisalo-Repo. 2002. Campylobacter-triggered reactive arthritis: a population-
based study. Rheumatology (Oxford) 41:312-318. 
37. Hayes, F. 2003. Toxins-antitoxins: plasmid maintenance, programmed cell death, and 
cell cycle arrest. Science 301:1496-1499. 
38. Ho, T. W., B. Mishu, C. Y. Li, C. Y. Gao, D. R. Cornblath, J. W. Griffin, A. K. 
Asbury, M. J. Blaser, and G. M. McKhann. 1995. Guillain-Barré syndrome in 
26 
 
northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid 
antibodies. Brain 118 ( Pt 3):597-605. 
39. Hofreuter, D., J. Tsai, R. O. Watson, V. Novik, B. Altman, M. Benitez, C. Clark, 
C. Perbost, T. Jarvie, L. Du, and J. E. Galán. 2006. Unique features of a highly 
pathogenic Campylobacter jejuni strain. Infect Immun 74:4694-4707. 
40. Hooper, D. C. 2001. Emerging mechanisms of fluoroquinolone resistance. Emerg 
Infect Dis 7:337-341. 
41. Iovine, N. M., S. Pursnani, A. Voldman, G. Wasserman, M. J. Blaser, and Y. 
Weinrauch. 2008. Reactive nitrogen species contribute to innate host defense against 
Campylobacter jejuni. Infect Immun 76:986-993. 
42. Jensen, R. B., and K. Gerdes. 1995. Programmed cell death in bacteria: proteic 
plasmid stabilization systems. Mol Microbiol 17:205-210. 
43. Johnson, E. P., A. R. Strom, and D. R. Helinski. 1996. Plasmid RK2 toxin protein 
ParE: purification and interaction with the ParD antitoxin protein. J Bacteriol 
178:1420-1429. 
44. Kasper, G., and N. Dickgiesser. 1985. Isolation from gastric epithelium of 
Campylobacter-like bacteria that are distinct from "Campylobacter pyloridis". Lancet 
1:111-112. 
45. Koga, M., M. Gilbert, J. Li, S. Koike, M. Takahashi, K. Furukawa, K. Hirata, 
and N. Yuki. 2005. Antecedent infections in Fisher syndrome: a common 
pathogenesis of molecular mimicry. Neurology 64:1605-1611. 
27 
 
46. Konkel, M. E., S. G. Garvis, S. L. Tipton, D. E. Anderson, and W. Cieplak. 1997. 
Identification and molecular cloning of a gene encoding a fibronectin-binding protein 
(CadF) from Campylobacter jejuni. Mol Microbiol 24:953-963. 
47. Lee, L. H., E. Burg, S. Baqar, A. L. Bourgeois, D. H. Burr, C. P. Ewing, T. J. 
Trust, and P. Guerry. 1999. Evaluation of a truncated recombinant flagellin subunit 
vaccine against Campylobacter jejuni. Infect Immun 67:5799-5805. 
48. Lehnherr, H., and M. B. Yarmolinsky. 1995. Addiction protein Phd of plasmid 
prophage P1 is a substrate of the ClpXP serine protease of Escherichia coli. Proc Natl 
Acad Sci U S A 92:3274-3277. 
49. Luechtefeld, N. A., M. J. Blaser, L. B. Reller, and W. L. Wang. 1980. Isolation of 
Campylobacter fetus subsp. jejuni from migratory waterfowl. J Clin Microbiol 
12:406-408. 
50. Magnuson, R. 2007. Hypothetical functions of toxin-antitoxin systems. J Bacteriol 
189:6089-6092. 
51. Magnuson, R., H. Lehnherr, G. Mukhopadhyay, and M. B. Yarmolinsky. 1996. 
Autoregulation of the plasmid addiction operon of bacteriophage P1. J Biol Chem 
271:18705-18710. 
52. Mead, G. C., W. R. Hudson, and M. H. Hinton. 1995. Effect of changes in 
processing to improve hygiene control on contamination of poultry carcasses with 
Campylobacter. Epidemiol Infect 115:495-500. 
53. Moser, I., W. Schroeder, and J. Salnikow. 1997. Campylobacter jejuni major outer 
membrane protein and a 59-kDa protein are involved in binding to fibronectin and 
INT 407 cell membranes. FEMS Microbiol Lett 157:233-238. 
28 
 
54. Moxon, E. R., P. B. Rainey, M. A. Nowak, and R. E. Lenski. 1994. Adaptive 
evolution of highly mutable loci in pathogenic bacteria. Curr Biol 4:24-33. 
55. Nachamkin, I., J. Liu, M. Li, H. Ung, A. P. Moran, M. M. Prendergast, and K. 
Sheikh. 2002. Campylobacter jejuni from patients with Guillain-Barré syndrome 
preferentially expresses a GD(1a)-like epitope. Infect Immun 70:5299-5303. 
56. NJ, S. 1992. Comparison of three methods for recovery of Campylobacter spp. from 
broiler carcasses, p. 663-666. In L. JE (ed.), vol. 55. Journal of Food Protection. 
57. Oosterom J, D. W. G., De Boer E, De Blaauw LH, Karman H. 1983. Survival of 
Campylobacter jejuni during poultry processing and pig slaughtering., vol. 46. 
Journal of Food Protection. 
58. Pandey, D. P., and K. Gerdes. 2005. Toxin-antitoxin loci are highly abundant in 
free-living but lost from host-associated prokaryotes. Nucleic Acids Res 33:966-976. 
59. Parker, C. T., W. G. Miller, S. T. Horn, and A. J. Lastovica. 2007. Common 
genomic features of Campylobacter jejuni subsp. doylei strains distinguish them from 
C. jejuni subsp. jejuni. BMC Microbiol 7:50. 
60. Parker, C. T., B. Quiñones, W. G. Miller, S. T. Horn, and R. E. Mandrell. 2006. 
Comparative genomic analysis of Campylobacter jejuni strains reveals diversity due 
to genomic elements similar to those present in C. jejuni strain RM1221. J Clin 
Microbiol 44:4125-4135. 
61. Parkhill, J., B. W. Wren, K. Mungall, J. M. Ketley, C. Churcher, D. Basham, T. 
Chillingworth, R. M. Davies, T. Feltwell, S. Holroyd, K. Jagels, A. V. Karlyshev, 
S. Moule, M. J. Pallen, C. W. Penn, M. A. Quail, M. A. Rajandream, K. M. 
Rutherford, A. H. van Vliet, S. Whitehead, and B. G. Barrell. 2000. The genome 
29 
 
sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable 
sequences. Nature 403:665-668. 
62. Patterson, M. F. 1995. Sensitivity of Campylobacter spp. to irradiation in poultry 
meat. Lett Appl Microbiol 20:338-340. 
63. Pearson, B. M., D. J. Gaskin, R. P. Segers, J. M. Wells, P. J. Nuijten, and A. H. 
van Vliet. 2007. The complete genome sequence of Campylobacter jejuni strain 
81116 (NCTC11828). J Bacteriol 189:8402-8403. 
64. Pedersen, K., S. K. Christensen, and K. Gerdes. 2002. Rapid induction and 
reversal of a bacteriostatic condition by controlled expression of toxins and 
antitoxins. Mol Microbiol 45:501-510. 
65. Pedersen, K., A. V. Zavialov, M. Y. Pavlov, J. Elf, K. Gerdes, and M. Ehrenberg. 
2003. The bacterial toxin RelE displays codon-specific cleavage of mRNAs in the 
ribosomal A site. Cell 112:131-140. 
66. Peterson, M. C. 1994. Clinical aspects of Campylobacter jejuni infections in adults. 
West J Med 161:148-152. 
67. Phongsisay, V., V. N. Perera, and B. N. Fry. 2007. Expression of the htrB gene is 
essential for responsiveness of Salmonella typhimurium and Campylobacter jejuni to 
harsh environments. Microbiology 153:254-262. 
68. Poly, F., T. Read, D. R. Tribble, S. Baqar, M. Lorenzo, and P. Guerry. 2007. 
Genome sequence of a clinical isolate of Campylobacter jejuni from Thailand. Infect 
Immun 75:3425-3433. 
69. Poly, F., T. D. Read, Y. H. Chen, M. A. Monteiro, O. Serichantalergs, P. 
Pootong, L. Bodhidatta, C. J. Mason, D. Rockabrand, S. Baqar, C. K. Porter, D. 
30 
 
Tribble, M. Darsley, and P. Guerry. 2008. Characterization of two Campylobacter 
jejuni strains for use in volunteer experimental-infection studies. Infect Immun 
76:5655-5667. 
70. Pullinger, G. D., and A. J. Lax. 1992. A Salmonella dublin virulence plasmid locus 
that affects bacterial growth under nutrient-limited conditions. Mol Microbiol 6:1631-
1643. 
71. Rice, B. E., D. M. Rollins, E. T. Mallinson, L. Carr, and S. W. Joseph. 1997. 
Campylobacter jejuni in broiler chickens: colonization and humoral immunity 
following oral vaccination and experimental infection. Vaccine 15:1922-1932. 
72. Ropper, A. H. 1992. The Guillain-Barré syndrome. N Engl J Med 326:1130-1136. 
73. Ruiz-Echevarría, M. J., M. A. de la Torre, and R. Díaz-Orejas. 1995. A mutation 
that decreases the efficiency of plasmid R1 replication leads to the activation of parD, 
a killer stability system of the plasmid. FEMS Microbiol Lett 130:129-135. 
74. Sahin, O., T. Y. Morishita, and Q. Zhang. 2002. Campylobacter colonization in 
poultry: sources of infection and modes of transmission. Anim Health Res Rev 3:95-
105. 
75. Sahin, O., P. Plummer, D. Jordan, K. Sulaj, S. Pereira, S. Robbe-Austerman, L. 
Wang, M. Yaeger, L. Hoffman, and Q. Zhang. 2008. Emergence of a tetracycline-
resistant Campylobacter jejuni clone associated with outbreaks of ovine abortion in 
the United States. J Clin Microbiol 46:1663-1671. 
76. Schumacher, M. A., K. M. Piro, W. Xu, S. Hansen, K. Lewis, and R. G. Brennan. 
2009. Molecular mechanisms of HipA-mediated multidrug tolerance and its 
neutralization by HipB. Science 323:396-401. 
31 
 
77. Shanker, S., A. Lee, and T. C. Sorrell. 1986. Campylobacter jejuni in broilers: the 
role of vertical transmission. J Hyg (Lond) 96:153-159. 
78. Skirrow, M. B., D. M. Jones, E. Sutcliffe, and J. Benjamin. 1993. Campylobacter 
bacteraemia in England and Wales, 1981-91. Epidemiol Infect 110:567-573. 
79. Sorvillo, F. J., L. E. Lieb, and S. H. Waterman. 1991. Incidence of 
campylobacteriosis among patients with AIDS in Los Angeles County. J Acquir 
Immune Defic Syndr 4:598-602. 
80. Takagi, H., Y. Kakuta, T. Okada, M. Yao, I. Tanaka, and M. Kimura. 2005. 
Crystal structure of archaeal toxin-antitoxin RelE-RelB complex with implications for 
toxin activity and antitoxin effects. Nat Struct Mol Biol 12:327-331. 
81. Taylor, D. N., K. T. McDermott, J. R. Little, J. G. Wells, and M. J. Blaser. 1983. 
Campylobacter enteritis from untreated water in the Rocky Mountains. Ann Intern 
Med 99:38-40. 
82. Tian, Q. B., M. Ohnishi, A. Tabuchi, and Y. Terawaki. 1996. A new plasmid-
encoded proteic killer gene system: cloning, sequencing, and analyzing hig locus of 
plasmid Rts1. Biochem Biophys Res Commun 220:280-284. 
83. van de Giessen, A. W., B. P. Bloemberg, W. S. Ritmeester, and J. J. Tilburg. 
1996. Epidemiological study on risk factors and risk reducing measures for 
Campylobacter infections in Dutch broiler flocks. Epidemiol Infect 117:245-250. 
84. van de Giessen, A. W., J. J. Tilburg, W. S. Ritmeester, and J. van der Plas. 1998. 
Reduction of Campylobacter infections in broiler flocks by application of hygiene 
measures. Epidemiol Infect 121:57-66. 
32 
 
85. Van Melderen, L., P. Bernard, and M. Couturier. 1994. Lon-dependent 
proteolysis of CcdA is the key control for activation of CcdB in plasmid-free 
segregant bacteria. Mol Microbiol 11:1151-1157. 
86. Van Melderen, L., and M. Saavedra De Bast. 2009. Bacterial toxin-antitoxin 
systems: more than selfish entities? PLoS Genet 5:e1000437. 
87. Vandamme, P. 2000. Taxonomy of the family Camplyobacteraceae, p. 3-26. In I. N. 
a. M. J. Blaser (ed.), Campylobacter, vol. 2nd ed. ASM Press, Washington, DC. 
88. Vogt, R. L., H. E. Sours, T. Barrett, R. A. Feldman, R. J. Dickinson, and L. 
Witherell. 1982. Campylobacter enteritis associated with contaminated water. Ann 
Intern Med 96:292-296. 
89. Wassenaar, T. M., B. N. Fry, A. J. Lastovica, J. A. Wagenaar, P. J. Coloe, and B. 
Duim. 2000. Genetic characterization of Campylobacter jejuni O:41 isolates in 
relation with Guillain-Barré syndrome. J Clin Microbiol 38:874-876. 
90. Yuki, N., T. Taki, F. Inagaki, T. Kasama, M. Takahashi, K. Saito, S. Handa, and 
T. Miyatake. 1993. A bacterium lipopolysaccharide that elicits Guillain-Barré 
syndrome has a GM1 ganglioside-like structure. J Exp Med 178:1771-1775. 
91. Zhang, M., L. He, Q. Li, H. Sun, Y. Gu, Y. You, F. Meng, and J. Zhang. 2010. 
Genomic characterization of the Guillain-Barré syndrome-associated Campylobacter 
jejuni ICDCCJ07001 Isolate. PLoS One 5:e15060. 
92. Zhang, M., Q. Li, L. He, F. Meng, Y. Gu, M. Zheng, Y. Gong, P. Wang, F. Ruan, 
L. Zhou, J. Wu, L. Chen, C. Fitzgerald, and J. Zhang. 2010. Association study 
between an outbreak of Guillain-Barré syndrome in Jilin, China, and preceding 
Campylobacter jejuni infection. Foodborne Pathog Dis 7:913-919. 
33 
 
93. Zhang, Y. X., J. Li, X. K. Guo, C. Wu, B. Bi, S. X. Ren, C. F. Wu, and G. P. 
Zhao. 2004. Characterization of a novel toxin-antitoxin module, VapBC, encoded by 
Leptospira interrogans chromosome. Cell Res 14:208-216. 
94. Zielenkiewicz, U., and P. Ceglowski. 2005. The toxin-antitoxin system of the 
streptococcal plasmid pSM19035. J Bacteriol 187:6094-6105. 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
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Abstract 
 
   Toxin-antitoxin systems are prevalent in different bacterial organisms and are encoded in 
the chromosomal or plasmid DNA.  The primary function of a plasmid toxin-antitoxin 
module is to stabilize the plasmid by eliminating plasmid-free daughter cells through a post 
segregation killing mechanism.  In C. jejuni, a pathogen that causes human gastroenteritis, 
multiple plasmids have been identified, but there have not been any reports on toxin-antitoxin 
systems.  In this study, a toxin-antitoxin system is identified and characterized in the pVir 
plasmid of C. jejuni IA 3902.  pVir encodes a type IV secretion system and is found to be 
involved in natural transformation and virulence.  Comparative genomic analysis of the 
pVir45 and pVir46 genes in C. jejuni indicates that they encode a putative toxin-antitoxin 
system that belongs to the RelE/StbE.  Cloning and expression of the pVir46 gene alone in 
Escherichia coli inhibited bacterial growth, but co-expression of pVir45-46 led to the 
restoration of growth confirming the functions deduced from comparative genomic analysis.  
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The plasmid stability assay in C. jejuni showed that the toxin-antitoxin system is necessary 
for maintaining the stability of pVir because deletion of the pVir46 gene resulted in loss of 
the plasmid during passage in conventional media.  qRT-PCR data demonstrated that 
expression of the pVir45-46 genes varied with growth phase, as early logarithmic phase had 
the highest level of gene expression.  Together these results establish that pVir45-46 encode 
a functional toxin-antitoxin system in C. jejuni, which is required for ensuring the stability of 
the pVir plasmid.  The stable maintenance of pVir may be necessary for optimal virulence of 
C. jejuni IA 3902. 
 
Introduction 
 
   C. jejuni is a spiral, microaerophilic, gram-negative organism associated with human 
gastroenteritis and increasingly with ovine abortions (3, 36).  Campylobacter is considered a 
highly infectious pathogen that causes diarrhea, headaches, and abdominal pain in humans 
and is mainly transmitted by the consumption of undercooked poultry meat, unpasteurized 
milk, and contaminated drinking water (5, 22, 28).  C. jejuni infections also trigger GBS, 
which is an autoimmune disorder that adversely affects the peripheral nervous system (35).  
Recently, there has been a species change in the etiology of ovine abortions in the United 
States because C. jejuni has replaced C. coli as the predominant cause of sheep abortion (20).  
The pathogenic mechanisms of C. jejuni are still poorly understood, and the reported 
virulence factors associated with C. jejuni survival and campylobacteriosis are motility, 
invasion and adhesion to epithelial cells, cytolethal distending toxin production, antibiotic 
susceptibility, and oxidative stress defense (8, 12, 19, 21, 31). 
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   Toxin-antitoxin (TA) systems are comprised of a pair of antagonistic genes that encode a 
stable toxin and an unstable antitoxin.  The toxin product primarily inhibits bacterial 
metabolic activity while the antitoxin binds to the toxin preventing its toxic activity (18).  
There are three types of TA systems:  type I systems are composed of RNA antitoxin, type II 
systems are composed of protein antitoxin, and type III systems are composed of RNA 
antisense and toxic protein (7, 16).  TA systems have been identified on bacterial plasmids 
and chromosomes.  The function of a plasmid-encoded TA system is for plasmid 
maintenance, in which a post-segregation killing mechanism is used to kill daughter cells that 
do not inherit a plasmid copy (9).  TA systems are found in multiple copies on the 
chromosome of several bacterial organisms, which has led to the speculation about the 
functions of this complex, including antiaddiction module, programmed cell death, growth 
control, persistence, and stabilization of genomic parasites (6, 14, 15, 32). 
 
   Comparative genomic analysis of C. jejuni genomes conducted by RASTA-Bacteria has 
identified that there are two potential TA systems:  one in the relBE and one in the vapBC 
family (34).  An early study using exhaustive BLAST searches indicate that there are no 
identifiable groups of toxin-antitoxin systems present in C. jejuni (27).  Recently, our 
laboratory has identified a gene (pVir46) on the pVir plasmid in C. jejuni IA3902, which has 
a significant sequence homology to relE that is a cytotoxic translational repressor of a TA 
system, suggesting the presence of a TA system in the pVir plasmid.   pVir45 is immediately 
up stream of pVir46 and these two genes appear to form an operon.  In this study, functional 
analysis of the pVir45 and pVir46 genes in C. jejuni IA 3902 is conducted by cloning and 
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expressing the genes in E. coli DH5α.  In addition, plasmid stability assay of pVir in C. jejuni 
is performed using pVir46 knock-out mutant in comparison with the wild-type plasmid.  
Results from these experiments indicated that pVir45 and pVir46 indeed encode a TA system 
in Campylobacter. 
 
Materials and Methods 
 
   Bacterial strains, plasmids, and culture conditions.  The bacterial strains, plasmids, and 
mutant constructs used in this study are listed in Table 1.  Mueller-Hinton (MH) agar or broth 
(Difco, Franklin Lakes, NJ) were used for the isolation and cultivation of C. jejuni strains.  
These Campylobacter strains were incubated at a temperature of 42 
o
C and grown under 
microaerophilic conditions (5% O2, 10% CO2, and 85% N2).  E. coli strains are grown in 
Luria Bertani (LB) agar or broth (Difco) at 37 
o
C with shaking at 200 rpm.  The selective 
media were supplemented with ampicillin (Amp) (100 μg/ml) or kanamycin (Km) (50 μg/ml) 
as needed for culturing E. coli or C. jejuni strains. 
 
   Nucleotide sequence database and software.  The complete genome of the pVir plasmid 
in C. jejuni IA 3902 was obtained from the NCBI Nucleotide Database 
(http://www.ncbi.nlm.nih.gov/).  The nucleotide sequence of pVir45 and pVir46 were 
analyzed by the Basic Local Alignment and Search Tool (BLAST) to determine their 
homology to previously annotated toxin-antitoxin systems in other bacterial organisms.  
Multiple sequence alignments were performed with ClustalW (Pathema, USA).  The 
promoter of pVir45 and pVir46 are determined by BPROM (Softberry, Mount Kisco, NY).  
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Rapid Automated Scan for Toxin and Antitoxins in Bacteria (RASTA-Bacteria) 
(http://genoweb.univ-rennes1.fr/duals/RASTA-Bacteria/) was also used to identify potential 
toxin-antitoxin systems in the pVir plasmid of C. jejuni IA 3902. 
 
   Expression of pVir45-46 genes in Escherichia coli DH5α.  The pVir45 and pVir46 genes 
were inserted downstream of the pBAD promoter in the multiple cloning site II of the 
arabinose inducible pBAD30 plasmid (Fig. 1).  The PCR amplification of the genes of 
interest were accomplished by designing PCR primers that incorporate the restriction sites of 
EcoRI followed by the ribosomal binding site in the forward direction and XbaI in the 
reverse direction.  PCR primers are utilized to amplify pVir45 and pVir46 genes as well as 
the pVir45-46 operon as shown in Table 2.  The PCR reactions were performed using the 
Eppendorf Gradient Thermocycler (Eppendorf, Hamburg, Germany) and the following 
conditions:  initial denaturation cycle of 95 
o
C for 5 minutes; 35 cycles at 95 
o
C for 30 
seconds, 50 
o
C for 30 seconds, and 72 
o
C for 1 minute; and a final extension cycle of 72 
o
C 
for 10 minutes.  The genomic DNA of C. jejuni IA 3902 was used as the DNA template for 
the PCR reactions.  After PCR amplification, the toxin-antitoxin gene products were purified 
with the QIAquick PCR purification kit (Qiagen, Venio, Netherlands).  Double digestion of 
the PCR products and the pBAD30 vector with the restriction enzymes of EcoRI and XbaI 
(New England Biolabs, Ipswich, MA) were performed at a temperature of 37 
o
C for 2 hours 
and then the reactions were purified with the QIAquick PCR purification kit (Qiagen).  The 
digested gene products were ligated into the pBAD30 vector using the Roche ligation kit 
(Roche Applied Science, Penzberg, Germany).  The ligation reactions were transformed into 
E. coli DH5α competent cells (Invitrogen, Carlsband, CA) and transformants were selected 
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with ampicillin (100 μg/ml).  The correct inserts in the transformants were confirmed by 
PCR. 
 
   Bacterial growth curve.  The objective of measuring bacterial growth curve was to 
determine if the individual toxin gene in the expression vector pBAD30 inhibits the growth 
of E. coli in the presence of an arabinose inducer.  The growth curves of E. coli DH5α 
containing an empty control vector, antitoxin, toxin, or the toxin-antitoxin system were 
determined by making measurement of OD600nm for eight hours after the induction with 0.2% 
arabinose or glucose in LB broth.  Prior to the induction, the bacterial cultures were grown in 
the Forma Orbital Shaker (Thermo Fisher, Waltham, MA) for approximately 16 hours at 200 
rpm at 37 
o
C.  The cultures were diluted 100x fold in LB broth for two hours to reach the 
mid-logarithmic (OD600 0.4).  After two hours of shaking, 0.2% arabinose or glucose inducer 
was added to determine if the cloned genes affected the growth of E. coli DH5α. After 
initiating the induction, hourly measurement of OD600nm was conducted for 8 hours.  An 
independent trial of triplicate replicates are used to verify the growth inhibition results 
obtained from these experimental trials. 
 
   Mutagenesis of pVir46 in C. jejuni.  A kanamycin resistance cassette was inserted into 
pVir46 located in the pVir plasmid of C. jejuni by insertional mutagenesis shown in Figure 
1B.  This was accomplished by using the primers of pVir46-F1 and pVir46-R1 (Table 1) to 
amplify a region of approximately 1476 base pair (bp) in the pVir plasmid.  The pVir primers 
were incorporated with the recognition sites of EcoRI and KpnI to the 5 prime end to 
facilitate the cloning of the PCR product into the pGEM®-T vector (Promega, Fitchburg, 
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WI).  After PCR amplification, the PCR product was purified with the QIAquick PCR 
purification kit (Qiagen) and ligated into the pGEM®-T vector (Promega) using the Roche 
ligation kit (Roche Applied Sciences).  The ligation reaction was transformed into E. coli 
DH5α (Invitrogen). The transformants with the PCR product inserted in the correct 
orientation in the pGEM®-T vector (Promega) were confirmed by PCR. 
 
   Once the pVir46-containing fragment was cloned into the pGEM®-T vector, inverse PCR 
using ex Taq polymerase (Takara, Shiga, Japan) was conducted to create a deletion of 
approximately 200 bp within the pVir46 gene.  The kanamycin resistance gene (Kan
R
) was 
amplified from the pMW10 plasmid using the ex Taq polymerase (Takara) was ligated with 
the inverse PCR product to make pGEM®-T-46K.  The ligation reaction was transformed 
into E. coli DH5α and the transformants were selected with100 μg/ml of ampicillin and 50 
μg/ml of kanamycin.  The insertion of the kanamycin resistance gene into pVir46 was 
confirmed by PCR.  The plasmid, pGEM®-T-46K, was extracted from E. coli DH5α with the 
Qiagen miniprep kit (Qiagen) and was introduced into C. jejuni IA3902 by electroporation. 
Then the Campylobacter cells were plated onto the MH agar plates containing kanamycin 
(50 μg/ml). Since pGEM®-T-46K was not able to replicate in Campylobacter, the selection 
with kanamycin resulted in the generation of mutants with the resistance gene inserted in 
pVir46.  PCR was used to verify the creation of the pVir46 mutant.  A motility assay was 
performed in triplicate to verify that the mutation did not affect the motility of C. jejuni strain 
IA3902. 
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   Plasmid stability of pVir46 mutant.  A plasmid stability assay was conducted to 
determine if the TA system affects the stability of the pVir plasmid in C. jejuni.  Since the 
wild-type pVir plasmid does not carry a selection marker, it was necessary to tag the plasmid 
to monitor its stability. Thus we used the pVirB10 mutant previously in our laboratory as a 
control to the pVir46 mutant.  The pVirB10 mutant had a kanamycin resistance marker 
inserted into the VirB10 gene, which inactivated the function (type IV secretion) of virB10, 
but the TA module was intact.  Single colonies of the pVir46 and pVirB10 mutant are picked 
from MH plates containing kanamycin and inoculated into 5 ml MH broth at 42 
o
C for 24 
hours.  A volume of 100 µl of the previous culture growth is reinoculated in MH broth and 
continued in this manner for 35 days.  A volume of 100 µl samples of pVir46 and pVirB10 
mutants are serially diluted and plated on MH.  After 48 hours, 100 colonies are randomly 
selected and inoculated to MH kanamycin plates.  The ratio of the colonies grown on the MH 
kanamycin is compared with the total viable count to determine the percentage of plasmid 
retained in the population. 
 
   Distribution of the toxin-antitoxin genes in different C. jejuni strains.  A pair of PCR 
primers was designed to detect the toxin-antitoxin system in various isolates of 124 C. jejuni 
obtained from sheep (58), broiler (18), turkey (23), and humans (25).  Total DNA of different 
C. jejuni isolates were obtained by the boiling method. The bacterial cells in 50 μl of water 
were boiled for approximately 10 minutes and then the supernatant was harvested by a 
centrifugation step.  PCR primers utilized to amplify the TA system and the pVirB10 gene 
are shown in Table 2.  The PCR reaction was prepared with a total volume of 25 μl 
containing 1 μl of DNA template, 10x Taq buffer (100 mM Tris-HCl, 500 mM KCl, 15 mM 
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MgCl2), 2.5 mM deoxynucleoside triphosphate mixture, 5 pM each primer, and 5 units of ex 
Taq polymerase (Takara).  The PCR parameters using the Eppendorf Gradient Thermocycler 
(Eppendorf) were as follows:  an initial denaturation cycle of 95 
o
C for 5 minutes; 35 cycles 
at 95 
o
C for 30 seconds, 52 
o
C for 30 seconds, and 72 
o
C for 1 minute; and a final extension 
cycle of 72 
o
C for 10 minutes.  The PCR reactions were examined by 1% agarose gels to 
determine if products for the target genes were amplified. 
 
   Reverse Transcription PCR analysis.  Reverse transcription PCR (RT-PCR) was 
performed to verify the expression of toxin-antitoxin module in C. jejuni IA 3902 obtained 
by using RNeasy minikit (Qiagen).  Total RNA was purified from IA3902 using the RNeasy 
minikit (Qiagen).  To prevent false positive results in RT-PCR, the isolated RNA sample was 
further treated with Ambion DNase I (Applied Biosystems, Foster City, CA) to remove DNA 
contamination.  A Nanodrop microscale spectrophotometer (Thermo Scientific) was used to 
access the quality and quantity of the RNA.  RT-PCR primers were designed to amplify both 
pVir45 and pVir46 of the TA system and are shown in Table 2.  RT-PCR was performed by 
using SuperScript
TM
 III One-Step RT-PCR System with Platinum
®
 Taq DNA Polymerase 
(Invitrogen).  The RT-PCR cycling conditions were the following:  initial denaturation cycle 
of 95 
o
C for 5 minutes; 35 cycles at 95 
o
C for 30 seconds, 52 
o
C for 30 seconds, and 72 
o
C for 
1 minute; and a final extension cycle of 72 
o
C for 10 minutes.  In negative control reaction 
for DNA contamination, the PCR mix contained Taq polymerase (Promega) without the RT 
step. 
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   Real-Time quantitative PCR.  Real-time quantitative PCR (qRT-PCR) was employed to 
determine the rate of transcription of the toxin-antitoxin module in relation to the growth 
phase of C. jejuni IA 3902.  Total RNA was isolated from C. jejuni grown under 
microaerophilic conditions at different incubation times (3 to 24 hours) using the RNeasy 
minikit (Qiagen).  The isolated RNA sample was further treated with Ambion DNase I 
(Applied Biosystems) to remove DNA contamination.  qRT-PCR was performed by using 
the MyiQ iCycler real-time PCR detection system (Bio-Rad, Hercules, CA).  A 10-fold 
dilution series between 2.5 pg and 25 ng were prepared for each RNA sample for qRT-PCR 
using iScript One-step RT-PCR kit with SYBR Green (Bio-Rad).  Primers were designed 
specifically for the pVir45, pVir46, and 16S rRNA genes by using the Primer3 online 
interface (http://frodo.wi.mit.edu/primer3/).  The primers used for qRT-PCR are listed in 
Table 2.  The gene expression of the TA system was normalized with the reference gene, 16S 
rRNA.  The qRT-PCR was performed as described in our previous publication (23).  The 
change in gene expression of the toxin-antitoxin module was determined by the 2
-ΔΔCT 
method (24). 
 
Results 
 
   Sequence analysis identifies a putative TA system in C. jejuni IA3902.  C. jejuni 
IA3902 harbors a pVir plasmid that is similar to the pVir plasmid identified in C. jejuni 81-
176, but has a few unique genes, such as pVir45 and pVir46.  The RASTA-Bacteria analysis 
indicates that the pVir46 gene has a significant amino acid identity of 19% ( E Value – 5e-4) 
with RelE, a cytotoxic translational repressor of the TA system (34).  The function of RelE is 
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to inhibit translation by targeting ribosomal RNA and triggering hydrolytic cleavage at the 
mRNA A site (29).  RASTA-Bacteria assigned the open reading frames of the pVir45 and 
pVir46 to previously annotated toxin-antitoxin pairs.  The pVir45 and pVir46 genes have a 
score of 60.73 and 70.75 calculated based on a scoring model adapted from a previous study 
suggesting that there is a great likelihood that the two genes form a TA system in the pVir 
plasmid (27). 
 
   According to the BLAST search, the pVir45 ORF shows a significant sequence homology 
to two uncharacterized putative proteins in C. jejuni subspecies doylei strain ATCC BAA-
1458 and Helicobacter pullorum MIT 98-5489 with a sequence identity of 96% and 73%, 
respectively.  The lack of sequence identity of pVir45 with known antitoxin sequences 
suggests that it is evolutionarily distant and diverse from the other antitoxin genes.  On the 
contrary, the BLAST search revealed that the pVir46 gene shows high amino acid identity 
with RelE.  The BLAST search of pVir46 gene has a sequence identity of 85% to an 
addiction module toxin in the chromosome of Helicobacter pullorum MIT 98-5489.  The 
pVir46 gene has 100% sequence identity to an uncharacterized putative protein in C. jejuni 
subspecies doylei strain ATCC BAA-1458 (Fig. 2).  
 
   Characteristics of the pVir45 and pVir46 genes in C. jejuni.   pVir45 is 285 bp in length 
and encodes a putative protein of 94 amino acids, while pVir46 is 276 bp in length and 
encodes a putative protein of 91 amino acids.  The predicted protein molecular mass of 
pVir45 and pVir46 are 22.9 and 22.6 kDA, respectively.  The overlap between the 
translational start site of pVir46 and the termination stop codon of pVir45 strongly suggests 
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transcriptional coupling and coexpression of this gene pair.  A schematic diagram of the 
genomic organization of the pVir45 and pVir46 genes and its promoter region is depicted in 
Figure 3. RT-PCR was used to determine if co-transcription occurs between pVir45 and 
pVir46.  The primers of pVir45int-F and pVir46int-F were designed to amplify an expected 
product of 260 bp that spans both pVir45 and pVir46.  As shown in Figure 4, a RT-PCR 
product of 260 bp was obtained with the RNA template, but no product was seen in the 
control reaction without the RT step.  This result suggests that pVir45 and pVir46 are 
expressed in C. jejuni and are cotranscribed as a single transcriptional unit. 
 
   pVir46 is toxic to E. coli.  To functionally characterize the TA system, we cloned pVir45 
and pVir46 into E. coli and measured their toxicity to the E. coli host. These E. coli 
constructs contained either an empty pBAD30 vector, a cloned pVir45, pVir46, or both. First, 
the growth of various E. coli constructs was measured on LB plates. In the absence of an 
inducer or presence of glucose, none of the cloned genes affected E. coli growth (Fig. 5). 
However, when arabinose was added to the plate, the E. coli containing the cloned pVir46 
gene stopped growth, while the other E. coli hosting the constructs grew normally, 
suggesting that pVir46 is toxic to E. coli.  To further examine the growth dynamics, we 
measured the growth rates of the E. coli constructs in LB broth. All of the constructs showed 
similar growth characteristics in the presence of glucose (Fig. 6). However, under the 
induction by arabinose, the E. coli harboring the cloned pVir46 gene showed little growth, 
while other constructs including those harboring pVir45 or both pVir45 and pVir46 grew 
normally as the E coli carrying an empty pBAD30 vector (Fig 6). Together, these results 
indicate that the pVir46 gene is an addiction module toxin that significantly impairs bacterial 
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growth when cloned and expressed into E. coli. The results also suggest pVir45 encodes an 
antitoxin because co-expression of pVir45 and pVir46 neutralized the toxicity of pVir46. 
 
   The TA system affects the stability of pVir in Campylobacter.  The TA system in pVir of 
C. jejuni IA3902 was inactivated to assess its effect on plasmid stability.  The result showed 
that the control pVir plasmid (with a mutation in pVirB10) was stably maintained during the 
prolonged passage in MH broth without any antibiotic selective pressures, because 100% of 
the bacterial colonies contained the plasmid even at the end of the 35 days passage (Fig. 7).  
On the contrary, the pVir46-negative plasmid, in which the addiction toxin gene was 
inactivated by insertional mutation, was unstable during the passage in MH broth and was 
gradually lost. In fact, only 11% of the bacterial cells retained the plasmid after 35 days of 
passage (Fig. 7).  These results clearly showed that this TA system is necessary for the 
genetic stability of the pVir plasmid in C. jejuni. 
 
   Detection of the pVir45/46 toxin-antitoxin system in C. jejuni.  A PCR-based screening 
method was used to determine the distribution of this TA system in C. jejuni isolates from 
different host species.  The primer pair of pVir45-F1 and pVir46-R1 was used to amplify a 
260 bp amplicon that spans both pVir45 and pVir46.  C. jejuni IA3902 was used as a positive 
control. Among all of the 124 C. jejuni isolates examined in this study, only one isolate, L4-
F3, from a sheep slaughter showed a positive amplification by the primers.  The TA module 
is not widely distributed in C. jejuni isolates. 
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   Growth phase regulated expression of the TA system.  Real-time quantitative PCR was 
conducted to determine the expression of the TA system at different growth phases. The 
results indicated that the expression levels of pVir45 and pVir46 decreased as the growth 
time increased (Table 3).  The greatest expression of the two genes occurred at the early log 
phase, while the lowest expression of the genes was observed at the stationary phase as 
expression was compared to the 3 hour growth phase.  The toxin gene expression initially 
starts with a threefold decrease during log phase (6 hours), then has a sevenfold decrease in 
the mid log phase (9 hours) and fourfold decrease in the late log phase (12 hours), and finally 
ends with a tenfold decrease at the stationary phase (24 hours).  This data reveals a trend of 
decreasing expression of the TA system associated with the growth phase. 
 
Discussion 
 
   In this study, we characterized a relBE-type toxin-antitoxin system in the pVir plasmid of 
C. jejuni IA3902.  The pVir45 and pVir46 genes represent the first identified TA stability 
complex discovered in C. jejuni species.  The toxicity of pVir46 to bacterial cells was clearly 
shown by cloning and expression of the pVir45, pVir46, or pVir45-46 genes in E. coli DH5α 
consistent with the pVir45 gene encoding an antitoxin that neutralizes the toxicity of pVir46.  
Thus the pVir45 and pVir46 genes constitute a functional TA system in Campylobacter. We 
further showed that this TA is essential for the maintenance of the pVir plasmid. Since pVir 
is a virulence plasmid in C. jejuni, retention of pVir may enhance the virulence of C. jejuni. 
Thus the identified TA system indirectly contributes to Campylobacter virulence by 
maintaining the stability of the pVir plasmid. 
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   The multiple sequence alignments suggest that the identified TA system in this study is a 
member of the relBE family.  The amino acid sequence conservation in TA systems is not 
well conserved, but it is clearly evident that the genetic organization is similar to other TA 
systems.  For example, parD and ccD genes have a weak sequence homology with previously 
annotated TA systems, but they belong to the same family based on similar genetic structure 
and functional characteristics.  Even though there is not tremendous protein sequence 
similarity in the relBE family, TA systems share similar genomic organization allowing for 
identification. 
 
   The expression of the TA system is growth phase regulated as its gene expression is more 
active in the logarithmic phase compared to the stationary phase.  These experimental results 
suggest that the relBE TA system in C. jejuni is down regulated during the stationary phase, 
possibly indicating that the TA system inhibits its response under unfavorable growth and 
environmental conditions, but has increased expression in more favorable situations.  TA 
systems are expressed differently or altered under different environmental or nutritional 
stimuli in response to thermal stress response, oxidative stress, and DNA damage (4, 17).   
 
  The data from the cloning and expression of pVir45, pVir46, and pVir45-46 in E. coli 
DH5α exhibited characteristics of a TA system.  It is evident that E. coli growth was 
significantly impaired when pVir46 was expressed.  Although it is conclusive that the pVir46 
gene encodes a bacterial toxin, but it is unknown at this stage if the toxin is bacteriostatic or 
bactericidal.  Additionally, it is unknown how pVir46 inhibits bacterial growth. Since it is a 
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member of the RelBE family, it is possible that the toxin targets translation, but this 
possibility remains to be determined in future studies.  The plasmid stability test indicates 
that the TA system is associated with pVir maintenance in Campylobacter.  This is consistent 
with findings in other bacteria that TA systems carried in plasmids are associated with 
plasmid stability.  
 
   The distribution of the relBE toxin-antitoxin system is not widely prevalent in the C. jejuni 
population.  We employ a PCR screening method to detect the presence of the TA system, 
however some variation of sequences in the primer binding region would render 
Campylobacter strains with TA negative by our assay (26).  The lack of a wide distribution 
of TA systems in C. jejuni could be explained by the speculation that horizontal gene transfer 
of the TA system to Campylobacter is a recent evolutionary event.  BLAST searches in 
different bacterial species indicate that the antitoxin gene is not as conserved as the toxin 
gene, and this lack of nucleotide conservation could lead to the lack of detection of the TA 
system in various C. jejuni isolates. 
 
References 
 
1. Aizenman, E., H. Engelberg-Kulka, and G. Glaser. 1996. An Escherichia coli 
chromosomal "addiction module" regulated by guanosine [corrected] 3',5'-
bispyrophosphate: a model for programmed bacterial cell death. Proc Natl Acad Sci 
U S A 93:6059-6063. 
50 
 
2. Amitai, S., Y. Yassin, and H. Engelberg-Kulka. 2004. MazF-mediated cell death in 
Escherichia coli: a point of no return. J Bacteriol 186:8295-8300. 
3. Black, R. E., M. M. Levine, M. L. Clements, T. P. Hughes, and M. J. Blaser. 
1988. Experimental Campylobacter jejuni infection in humans. J Infect Dis 157:472-
479. 
4. Cooper, C. R., A. J. Daugherty, S. Tachdjian, P. H. Blum, and R. M. Kelly. 2009. 
Role of vapBC toxin-antitoxin loci in the thermal stress response of Sulfolobus 
solfataricus. Biochem Soc Trans 37:123-126. 
5. Engberg, J., P. Gerner-Smidt, F. Scheutz, E. Møller Nielsen, S. L. On, and K. 
Mølbak. 1998. Water-borne Campylobacter jejuni infection in a Danish town---a 6-
week continuous source outbreak. Clin Microbiol Infect 4:648-656. 
6. Engelberg-Kulka, H., R. Hazan, and S. Amitai. 2005. mazEF: a chromosomal 
toxin-antitoxin module that triggers programmed cell death in bacteria. J Cell Sci 
118:4327-4332. 
7. Fineran, P. C., T. R. Blower, I. J. Foulds, D. P. Humphreys, K. S. Lilley, and G. 
P. Salmond. 2009. The phage abortive infection system, ToxIN, functions as a 
protein-RNA toxin-antitoxin pair. Proc Natl Acad Sci U S A 106:894-899. 
8. Gaudreau, C., and H. Gilbert. 2003. Antimicrobial resistance of Campylobacter 
jejuni subsp. jejuni strains isolated from humans in 1998 to 2001 in Montréal, 
Canada. Antimicrob Agents Chemother 47:2027-2029. 
9. Gerdes, K., P. B. Rasmussen, and S. Molin. 1986. Unique type of plasmid 
maintenance function: postsegregational killing of plasmid-free cells. Proc Natl Acad 
Sci U S A 83:3116-3120. 
51 
 
10. Gordon, G. S., D. Sitnikov, C. D. Webb, A. Teleman, A. Straight, R. Losick, A. 
W. Murray, and A. Wright. 1997. Chromosome and low copy plasmid segregation 
in E. coli: visual evidence for distinct mechanisms. Cell 90:1113-1121. 
11. Gotfredsen, M., and K. Gerdes. 1998. The Escherichia coli relBE genes belong to a 
new toxin-antitoxin gene family. Mol Microbiol 29:1065-1076. 
12. Grant, C. C., M. E. Konkel, W. Cieplak, and L. S. Tompkins. 1993. Role of 
flagella in adherence, internalization, and translocation of Campylobacter jejuni in 
nonpolarized and polarized epithelial cell cultures. Infect Immun 61:1764-1771. 
13. Guzman, L. M., D. Belin, M. J. Carson, and J. Beckwith. 1995. Tight regulation, 
modulation, and high-level expression by vectors containing the arabinose PBAD 
promoter. J Bacteriol 177:4121-4130. 
14. Han, J. S., J. J. Lee, T. Anandan, M. Zeng, S. Sripathi, W. J. Jahng, S. H. Lee, J. 
W. Suh, and C. M. Kang. 2010. Characterization of a chromosomal toxin-antitoxin, 
Rv1102c-Rv1103c system in Mycobacterium tuberculosis. Biochem Biophys Res 
Commun 400:293-298. 
15. Harrison, J. J., W. D. Wade, S. Akierman, C. Vacchi-Suzzi, C. A. Stremick, R. J. 
Turner, and H. Ceri. 2009. The chromosomal toxin gene yafQ is a determinant of 
multidrug tolerance for Escherichia coli growing in a biofilm. Antimicrob Agents 
Chemother 53:2253-2258. 
16. Hayes, F. 2003. Toxins-antitoxins: plasmid maintenance, programmed cell death, and 
cell cycle arrest. Science 301:1496-1499. 
52 
 
17. Hazan, R., B. Sat, and H. Engelberg-Kulka. 2004. Escherichia coli mazEF-
mediated cell death is triggered by various stressful conditions. J Bacteriol 186:3663-
3669. 
18. Jensen, R. B., and K. Gerdes. 1995. Programmed cell death in bacteria: proteic 
plasmid stabilization systems. Mol Microbiol 17:205-210. 
19. Jeon, B., Y. Wang, H. Hao, Y. W. Barton, and Q. Zhang. 2011. Contribution of 
CmeG to antibiotic and oxidative stress resistance in Campylobacter jejuni. J 
Antimicrob Chemother 66:79-85. 
20. Kirkbride, C. A. 1993. Bacterial agents detected in a 10-year study of bovine 
abortions and stillbirths. J Vet Diagn Invest 5:64-68. 
21. Konkel, M. E., M. R. Monteville, V. Rivera-Amill, and L. A. Joens. 2001. The 
pathogenesis of Campylobacter jejuni-mediated enteritis. Curr Issues Intest Microbiol 
2:55-71. 
22. Kálmán, M., E. Szöllósi, B. Czermann, M. Zimányi, and S. Szekeres. 2000. 
Milkborne Campylobacter infection in Hungary. J Food Prot 63:1426-1429. 
23. Lin, J., C. Cagliero, B. Guo, Y. W. Barton, M. C. Maurel, S. Payot, and Q. 
Zhang. 2005. Bile salts modulate expression of the CmeABC multidrug efflux pump 
in Campylobacter jejuni. J Bacteriol 187:7417-7424. 
24. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 
25:402-408. 
53 
 
25. Mine, N., J. Guglielmini, M. Wilbaux, and L. Van Melderen. 2009. The decay of 
the chromosomally encoded ccdO157 toxin-antitoxin system in the Escherichia coli 
species. Genetics 181:1557-1566. 
26. Moritz, E. M., and P. J. Hergenrother. 2007. Toxin-antitoxin systems are 
ubiquitous and plasmid-encoded in vancomycin-resistant enterococci. Proc Natl Acad 
Sci U S A 104:311-316. 
27. Pandey, D. P., and K. Gerdes. 2005. Toxin-antitoxin loci are highly abundant in 
free-living but lost from host-associated prokaryotes. Nucleic Acids Res 33:966-976. 
28. Pearson, A. D., M. H. Greenwood, J. Donaldson, T. D. Healing, D. M. Jones, M. 
Shahamat, R. K. Feltham, and R. R. Colwell. 2000. Continuous source outbreak of 
campylobacteriosis traced to chicken. J Food Prot 63:309-314. 
29. Pedersen, K., A. V. Zavialov, M. Y. Pavlov, J. Elf, K. Gerdes, and M. Ehrenberg. 
2003. The bacterial toxin RelE displays codon-specific cleavage of mRNAs in the 
ribosomal A site. Cell 112:131-140. 
30. Radnedge, L., M. A. Davis, B. Youngren, and S. J. Austin. 1997. Plasmid 
maintenance functions of the large virulence plasmid of Shigella flexneri. J Bacteriol 
179:3670-3675. 
31. Russell, R. G., M. O'Donnoghue, D. C. Blake, J. Zulty, and L. J. DeTolla. 1993. 
Early colonic damage and invasion of Campylobacter jejuni in experimentally 
challenged infant Macaca mulatta. J Infect Dis 168:210-215. 
32. Saavedra De Bast, M., N. Mine, and L. Van Melderen. 2008. Chromosomal toxin-
antitoxin systems may act as antiaddiction modules. J Bacteriol 190:4603-4609. 
54 
 
33. Sahin, O., P. Plummer, D. Jordan, K. Sulaj, S. Pereira, S. Robbe-Austerman, L. 
Wang, M. Yaeger, L. Hoffman, and Q. Zhang. 2008. Emergence of a tetracycline-
resistant Campylobacter jejuni clone associated with outbreaks of ovine abortion in 
the United States. J Clin Microbiol 46:1663-1671. 
34. Sevin, E. W., and F. Barloy-Hubler. 2007. RASTA-Bacteria: a web-based tool for 
identifying toxin-antitoxin loci in prokaryotes. Genome Biol 8:R155. 
35. Shoenfeld, Y., J. George, and J. B. Peter. 1996. Guillain-Barré as an autoimmune 
disease. Int Arch Allergy Immunol 109:318-326. 
36. Varga, J., B. Mézes, L. Fodor, and I. Hajtós. 1990. Serogroups of Campylobacter 
fetus and Campylobacter jejuni isolated in cases of ovine abortion. Zentralbl 
Veterinarmed B 37:148-152. 
37. Wösten, M. M., M. Boeve, M. G. Koot, A. C. van Nuenen, and B. A. van der 
Zeijst. 1998. Identification of Campylobacter jejuni promoter sequences. J Bacteriol 
180:594-599. 
 
 
 
 
 
 
 
55 
 
 
 
 
 
TABLE 1.  Bacterial strains and plasmids used in the study 
Plasmid or strain Relevant characteristics Source or reference 
Strains   
   C. jejuni   
       IA 3902 Originally isolated from the placenta of 
aborted sheep 
(33) 
       pVir46
- Iowa 3902 derivative; pVir46
-
::Kan
r 
This study 
   
   E. coli   
 
      DH5α 
F
-ϕ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 
endA1-hsdR17 (rk
-
, mk
+
) phoA supE44 thi-1 
gyrA96 relA1 ɻ- endA1 recA1 gyrA96 thi 
hsdR17 (rk
-
, mk
+
) relA1
- 
Invitrogen 
   
Plasmids   
   pBAD30 araBAD promoter-based expression vector, 
p15a ori, Amp
r
 
(13) 
   pBAD30-45 pBAD30 containing full-length pVir45, Amp
r 
This study 
   pBAD30-46 pBAD30 containing full length pVir46, Amp
r 
This study 
   pBAD30-45-46 pBAD30 containing full length pVir45 and 
pVir46, Amp
r 
This study 
   pGEM®-T PCR cloning vector, Amp
r 
Promega 
   pMW10 E. coli- C. jejuni shuttle vector with 
promoterless lacZ gene, Kan
r 
(37) 
Additional C. jejuni strains from the origins of sheep, broiler, turkey, and clinical isolates are used for PCR 
screening that are not listed above. 
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TABLE 2.  Oligonucleotide primers used in the study 
Primer Primer Sequence
* 
pVir46f-F1 5’-TAAAGACAATATAAAACAGT-3’ 
pVir46f-R1 5’-CTATTTGATTGGATTATGTA-3’ 
pVir46inv-F1 5’-ATATTAATTAAGCTAATTTAGGAAATCACAA-3’ (PacI) 
pVir46inv-R1 5’-ATAGCTAGCTTATATCGCAATGAAAAAGA-3’ (NheI) 
aphA-3kan-F 5’-ATAGCTAGCATAGGCAGCGCGCTTATC-3’ (NheI) 
aphA-3kan-R 5’-ATATTAATTAACCACAATGATAGAACCAACGA-3’ (PacI) 
pVir45-F1 5’-ATAGAATTCAAGGAGTAAAAATGTTTGATTATT-3’ (EcoRI)  
pVir45-R1 5-CTTTCTAGAAAAGTAACGCTATATTTATTCTGCA-3’ (XbaI) 
pVir46-F1 5’-AGAGAATTCTAAGGCTTTAAATGCAGAATAA-3’ (EcoRI)  
pVir46-R1 5’-TATTCTAGATATATGTTTTTGTTATTTTTAGACT-3’ (XbaI) 
pVir45int-F 5’-AAAAAGCAGATCAAAGAAGA-3’ 
pVir46int-R 5’-TCCTTTTAGTGCGTGGTCT-3’ 
pVir45rt-F 5’-AAGCAGATCAAAGAAGACCTGAA-3’ 
pVir45rt-R 5’-AACGCTTCTTCTACATTGGCATA-3’ 
pVir46rt-F 5’-GAAAAATACAAAGACCACGCACT-3’ 
pVir46rt-R 5’-TGCGATAGACTAATAACAAATCAGG-3’ 
virB10-F 5’-CCGTCTAGATAGAATGATAAGAGCAGGAAG-3’   
virB10-R 5’-TAGCTGCAGCAAACCACATATGATTGGTAG-3’   
*The restriction sites are underlined and in bold in the primer sequences.  The names of the restriction enzymes 
are in the parenthesis. 
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TABLE 3.  Growth phase regulated expression of the TA system 
Gene 
Identification 
Description Growth time 
(Hours) 
Fold change by 
Real Time PCR 
(RT-PCR) 
pVir45 RelB Antitoxin   
  6 -3.29 
  9 -6.59 
  12 -3.78 
  24 -8.46 
    
pVir46 RelE Addiction Module Toxin   
  6 -2.64 
  9 -7.31 
  12 -4.38 
  24 -10.27 
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(A) 
   C. jejuni Iowa 3902 
          pVir45  pVir46        pVir47 
       
Kan
R 
 
   pVir46
-
  
        pVir45 pVir46         pVir47 
 
(B) 
 
" p B A D 3 0 . "  C V e c t o r .  W e b .  4  M a r  2 0 1 1 .  
< h t t p : / / g i l l n e t . l a b . n i g . a c . j p / ~ c v e c t o r / m a p / p B A D 3 0 . g i f > .  
FIG. 1.  Diagrams depicting the generation of the insertional mutation in C. jejuni IA3902 
and expression of the TA system in in E. coli.  (A)  A schematic diagram showing the 
deletion of the pVir46 gene and the insertion of a kanamycin resistance gene in its location in 
creating the pVir46
- 
mutant.  The boxed arrows indicate the genes while the black arrow 
represents Kan
R
.  (B)  A diagram showing the cloning and expression of the pVir45, pVir46, 
and pVir45-46 genes into the multiple cloning site of the pBAD30 plasmid.  The restriction 
sites are shown in black, which are EcoRI and XbaI. 
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(A) 
D3FPN5 MFDYSKYENATEKQLIHALTLAEKRAEKLNSQLKENNELFKFLQKKLKNSFNTKKTKKAD 61 
A7H3J5 MFDYSKYENATEKQLIHALTLAEKRAEKLNSQLKENNELFKFLQKKLKNSFSTKKTKKAE 61 
C5F1A5 MFDYAKYENATQKEIIHALNLTQRKSEKLNQQLKENREIFKFLQKKLKESFSSKKTKK-E 60 
       ****:******:*::****.*:::::****.*****.*:*********:**.:***** : 
 
D3FPN5 QRRPELDEAIEDYKNGNVEHYANVEEAFKALNAE 95 
A7H3J5 QRRPELDEAIEDYKNGNVEHYANVEEAFKALSAE 95 
C5F1A5 KRRPELDEAIRQYENGEVEHYSSVEEAFKALNAE 94 
       :*********.:*:**:****:.********.** 
 
(B) 
A7H3J6 MQNKYSVTFSKRFKKDFKKINNNDKKILKKIVNKLANDEVLEEKYKDHALKGNYA----- 56 
D3FPN6 MQNKYSVTFSKRFKKDFKKINNNDKKILKKIVNKLANDEVLEEKYKDHALKGNYIGFREC 61 
C5F1A4 MQNKYSITFSKQFKKDFKKINKDDKIILKNIVDKLANDETLEAKYKDHALKGNYIGFREC 61 
       ******:****:*********::** ***:**:******.** ***********       
 
A7H3J6 ------------QKTIKSI------------ 63 
D3FPN6 HIKPDLLLVYRKNNDILELYLANLGNHNNIF 92 
C5F1A4 HIKPDLLLIYRKRDDILELYLASLGNHNNIF 92 
                   .. * .:             
 
A7H3J – Helicobacter pullorum MIT 98-5489 
C5F1A – C. jejuni subsp. doylei 
D3FPN – C. jejuni IA 3902 
 
 
 
FIG. 2.  A multiple sequence alignment constructed by ClustalW to compare the amino acid 
identity of pVir45 and pVir46 genes of C. jejuni IA 3902 with Helicobacter pullorum MIT 
98-5489 and C. jejuni subsp. doylei (strain ATCC BAA-1458 / RM4099 / 269.97).  The 
asterisks indicate identical matches of amino acids and dots indicate conservation of similar 
amino acids below the multiple alignments.  The multiple sequence alignments of the 
antitoxin region (A) and toxin region (B) of C. jejuni Iowa 3902 are compared to the other 
bacterial organisms. 
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FIG.  3.  Genomic organization and sequence features of the toxin-antitoxin system in C. 
jejuni IA3902.  The promoter region and the ribosomal binding site are underlined.  The two 
ORFs overlap and the start codon of pVir46 is 5 nucleotides upstream of the stop codon of 
pVir45. 
 
 
 
 
              bp      1    2 
 
 
Fig. 4.  Expression operon of pVir45 and pVir46 in C. jejuni IA3902 as determined by RT-
PCR.  Primers are designed to amplify a region of 260 bp that spans both genes.  Lane 1 is 
the negative control reaction without the RT step and lane 2 is the reaction with RT. 
 
pVir45  pVir46 
TTAAAAAGATTTTTTAAAGTAAAAAAGTTATAATTTGTTTATATAAAATAAGGAGTAAAAATG 
-35 Region    -10 Region       RBS     
 
250 
750 
500 
1000 
260 bp 
         
ATGCAGAATAA 
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LB Amp
+
 (Control)    LB Amp
+
Ara
+ 
 
 
LB Amp
+
Glu
+
 
 
FIG. 5.  Growth of E. coli DH5α constructs containing an empty vector (1), the antitoxin (2), 
the toxin (3), and the TA system (4) on LB plates with ampicillin (Amp
+
), ampicillin plus 
arabinose (Amp
+
Ara
+
), or ampicillin plus glucose (Amp
+
Glu
+
). 
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(A) 
 
(B) 
 
Fig. 6.  Growth of various E. coli DH5α constructed containing an empty pBAD30 plasmid 
(control), cloned pVir45 (antitoxin), cloned pVir46 (toxin), and the entire TA system in LB 
broth added with (A) glucose or (B) arabinose. 
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FIG.  7.  Plasmid (pVir) stability assay as measured by passage in MH broth. This was done 
using C. jejuni IA3902, in which the pVir plasmid was inserted with an antibiotic resistance 
marker in either virB10 or pVir46. 
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CHAPTER 3.  General Conclusion 
 
   In this experimental study, we identified and characterized a two-gene operon of pVir45 
and pVir46 that comprises a TA stability system in the pVir plasmid of C. jejuni IA 3902.  
The genomic organization of pVir45 and pVir46 has a similar structure to TA systems 
identified in other bacterial organisms.  The overlap of the two ORFs suggests coexpression 
of the gene pair and RT-PCR further confirmed this possibility.  Expression of pVir46 alone 
in E. coli inhibited bacterial growth, but this inhibition was relieved when pVir-45 and pVir-
46 genes were coexpressed in the same host.  This finding indicates that the pVir46 gene 
encodes an addiction module toxin and pVir45 encodes an antitoxin that neutralizes the toxic 
effects of pVir46.  We further showed that this TA system is necessary for pVir stability in 
C. jejuni because mutation of pVir46 resulted in the loss of the pVir plasmid from the 
Campylobacter strain. Real-time qT-PCR showed that the expression of the TA system is 
growth phase regulated and its gene expression is highest in the logarithmic growth phase. 
 
   These results establish that pVir45 and pVir46 form a functional TA in C. jejuni, which 
represents the first TA system identified in any Campylobacter species.  The fact that it 
maintains the pVir plasmid, which is a known virulence factor in Campylobacter, suggests 
that this TA system contributes to the virulence and adaptation of this pathogenic organism in 
C. jejuni IA 3902. Future studies are needed to determine if additional TA systems are 
present in Campylobacter, how the pVir46 toxin produces its toxic effects, and how the 
expression of this TA system is regulated by growth phases. These studies will contribute to 
improved understanding of evolution of virulence and pathogenesis in Campylobacter. 
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